

Centrica plc

3 March 2025

**Update on Share Buyback Extension**

In its 2024 Preliminary Results on 20 February 2025, the Company announced a further £500 million extension of the Company's share buyback programme, to be completed by around the end of 2025 (the "**2025 Extension**"), taking the total programme to £2.0bn.

In order to facilitate the 2025 Extension, the non-discretionary agreement that the Company entered into with Merrill Lynch International ("**Merrill Lynch**") to conduct share repurchases on its behalf up to an aggregate consideration of £270 million (the "**2024-25 Extension**"), which the Company announced on 27 December 2024, has been amended so that the period during which Merrill Lynch will conduct such repurchases will now end no later than 13 June 2025 (instead of 26 September 2025 as previously announced). The parameters of the 2024-25 Extension otherwise remain as set out in the announcement on 27 December 2024.

The Company further announces that, following the purchase of shares on 28 February 2025, Goldman Sachs International has concluded its purchase of shares pursuant to the non-discretionary agreements with the Company announced on 8 August 2024 and 27 December 2024. Pursuant to these agreements, the Company has repurchased 181,529,791 ordinary shares in aggregate at an average execution price of 126.70 pence per ordinary share for a total consideration (excluding dealing and associated costs) of approximately £229,999,334.

Enquiries:  
Investors and Analysts  
E: [ir@centrica.com](mailto:ir@centrica.com)

Media  
T: 01784 843000  
E: [media@centrica.com](mailto:media@centrica.com)

END

Centrica plc is listed on the London Stock Exchange (CNA)  
Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD  
Registered in England & Wales number: 3033654  
Legal Entity Identifier number: E26EDV109X6EEPBKVH76  
ISIN number: GB00B033F229

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCZLLFBEXLLBBL